Quick Takeaways
- Foundation Fighting Blindness Retinal Degeneration Fund filed SCHEDULE 13D/A for Opus Genetics, Inc. Common Stock, $0.0001 par value per share (IRD).
- Disclosed ownership: 16%.
- Date of event: 30 Apr 2025.
Foundation Fighting Blindness Retinal Degeneration Fund - 30 Apr 2025 SCHEDULE 13D/A Report for Opus Genetics, Inc. Common Stock, $0.0001 par value per share (IRD)
- Filing Manager
- Foundation Fighting Blindness Retinal Degeneration Fund
- Reporting Manager
- Foundation Fighting Blindness Retinal Degeneration Fund
- Symbol
- IRD
- Shares outstanding
- 59,699,189 shares
- Disclosed Ownership
- 9,492,171 shares
- Ownership
- 16%
- Form type
- SCHEDULE 13D/A
- Filing time
- 06 May 2025, 17:55:07 UTC
- Date of event
- 30 Apr 2025
- Next filing
- 11 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Foundation Fighting Blindness Retinal Degeneration Fund disclosed 16% ownership in Opus Genetics, Inc. Common Stock, $0.0001 par value per share (IRD) on 30 Apr 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 06 May 2025, 17:55.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | 16% | 9,492,171 | 0 | 9,492,171 | /s/ Russell Kelley | Russell Kelley, Managing Director | 0002042266 |
| Foundation Fight Blindness, Inc. | 16% | 9,492,171 | 0 | 9,492,171 | /s/ Jason Menzo | Jason Menzo, Chief Executive Officer |